The product is licensed by clients such as aging-in-place facilities, wellness-focused businesses, care management organizations, health systems, and employee benefits leaders.
Enterprises can deploy the solution for use with a general managed population or an at-risk population, such as seniors, postoperative patients, those with health conditions, or new mothers.
Through an easy-to-use dashboard, an enterprise can survey, message and educate its population while the connected mobile App empowers and engages patients/employees and their families through alerts, journals, reminders, surveys, instant messaging, and tailored content.
Research by the American Heart Association indicates that incorporating family support and providing easy-to-read educational material to patients and their caregivers enhance medication adherence.
Another element of the App is targeted educational assistance (TEA), a health condition education content that is auto-delivered to the App from sources such as the National Library of Medicine.
The App also includes features to increase medication adherence. The dashboard also contains population health analytics tools tailored to the needs of the enterprise.
ICMed is a mobile patient & family engagement solution.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering